Revolution Medicines Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

RVMD$193.06-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholdersʼ
	Shares	Amount	Capital	Income/ (Loss)	Deficit	Equity
Balance at December 31, 2023	164,674,594	$16	$2,963,342	$544	$(1,137,708)	$1,826,194
Issuance of common stock pursuant to stock option exercises	73,342	—	810	—	—	810
Issuance of common stock related to vesting of restricted stock units	165,078	—	—	—	—	—
Stock-based compensation expense	—	—	16,208	—	—	16,208
Net unrealized loss on marketable securities	—	—	—	(1,742)	—	(1,742)
Net loss	—	—	—	—	(116,003)	(116,003)
Balance at March 31, 2024	164,913,014	$16	$2,980,360	$(1,198)	$(1,253,711)	$1,725,467
Issuance of common stock pursuant to stock option exercises	238,793	—	4,340	—	—	4,340
Issuance of common stock related to vesting of restricted stock units	303,953	—	—	—	—	—
Issuance of common stock related to employee stock purchase plan	190,748	—	3,164	—	—	3,164
Stock-based compensation expense	—	—	19,775	—	—	19,775
Net unrealized loss on marketable securities	—	—	—	(665)	—	(665)
Net loss	—	—	—	—	(133,233)	(133,233)
Balance at June 30, 2024	165,646,508	$16	$3,007,639	$(1,863)	$(1,386,944)	$1,618,848
Issuance of common stock pursuant to stock option exercises	218,318	—	3,001	—	—	3,001
Issuance of common stock related to vesting of restricted stock units	255,934	—	—	—	—	—
Issuance of common stock upon at-the-market offering	1,627,576	—	74,293	—	—	74,293
Stock-based compensation expense	—	—	20,775	—	—	20,775
Net unrealized gain on marketable securities	—	—	—	5,675	—	5,675
Net loss	—	—	—	—	(156,288)	(156,288)
Balance at September 30, 2024	167,748,336	$16	$3,105,708	$3,812	$(1,543,232)	$1,566,304

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholdersʼ
	Shares	Amount	Capital	Loss	Deficit	Equity
Balance at December 31, 2022	90,411,912	$9	$1,388,300	$(1,780)	$(701,341)	$685,188
Issuance of common stock pursuant to stock option exercises	118,747	—	499	—	—	499
Issuance of common stock related to vesting of restricted stock units	85,891	—	—	—	—	—
Issuance of common stock from follow-on offering, net of offering costs of $21,294	15,681,818	2	323,704	—	—	323,706
Repurchase of early exercised stock	(291)	—	—	—	—	—
Stock-based compensation expense	—	—	9,699	—	—	9,699
Net unrealized gain on marketable securities	—	—	—	1,224	—	1,224
Net loss	—	—	—	—	(68,098)	(68,098)
Balance at March 31, 2023	106,298,077	$11	$1,722,202	$(556)	$(769,439)	$952,218
Issuance of common stock pursuant to stock option exercises	45,918	—	468	—	—	468
Issuance of common stock related to vesting of restricted stock units	174,252	—	—	—	—	—
Issuance of common stock related to employee stock purchase plan	139,967	—	2,109	—	—	2,109
Issuance of common stock upon at-the-market offering, net of issuance cost of $1,426	2,482,880	—	62,053	—	—	62,053
Stock-based compensation expense	—	—	12,980	—	—	12,980
Net unrealized loss on marketable securities	—	—	—	(695)	—	(695)
Net loss	—	—	—	—	(98,298)	(98,298)
Balance at June 30, 2023	109,141,094	$11	$1,799,812	$(1,251)	$(867,737)	$930,835
Issuance of common stock pursuant to stock option exercises	150,525	—	1,011	—	—	1,011
Issuance of common stock related to vesting of restricted stock units	160,066	—	—	—	—	—
Stock-based compensation expense	—	—	13,666	—	—	13,666
Net unrealized loss on marketable securities	—	—	—	380	—	380
Net loss	—	—	—	—	(108,434)	(108,434)
Balance at September 30, 2023	109,451,685	$11	$1,814,489	$(871)	$(976,171)	$837,458

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.